SCHEMBL6775795

SCHEMBL6775795

Fc1ccccc1-c1nnc2cc(Br)c(Cl)nn12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 3/20 0.45
HSD11B1 P28845 5/20 0.43
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
LRRK2 Q5S007 1/20 0.38
PDE2A O00408 1/20 0.38
PDE10A Q9Y233 1/20 0.38
POLB P06746 1/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
ALDH1A1 P00352 1/20 0.34
KCNN4 O15554 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6775681 0.83 HSD11B1 (0.43) DCTPP1HSD11B1GABRA1GABRG2GABRB3
SCHEMBL6519834 0.81 HSD11B1 (0.44) DCTPP1HSD11B1GABRA1GABRG2GABRB3
SCHEMBL6869998 0.80 HSD11B1 (0.43) DCTPP1HSD11B1GABRA1GABRG2GABRB3
SCHEMBL2656762 0.80 GABRA1 (0.54) DCTPP1HSD11B1GABRA1GABRG2GABRB3
SCHEMBL6768851 0.79 HSD11B1 (0.40) DCTPP1HSD11B1GABRA1GABRG2GABRB3
SCHEMBL31226152 0.77 HSD17B10 (0.49) LRRK2POLBNPSR1ALDH1A1
SCHEMBL6768850 0.77 GABRA1 (0.44) DCTPP1HSD11B1GABRA1GABRG2GABRB3
SCHEMBL6773557 0.77 ALDH1A1 (0.45) DCTPP1HSD11B1GABRA1GABRG2GABRB3
SCHEMBL6524041 0.77 GABRA1 (0.47) DCTPP1HSD11B1GABRA1GABRG2GABRB3
SCHEMBL15364544 0.77 SMN1; SMN2 (0.50) DCTPP1HSD11B1GABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828322-B2 Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine MERCK SHARP & DOHME LTD. 2004-12-07 US disclosed
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 US disclosed
US-6579875-B1 Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine MERCK SHARP & DOHME LIMITED 2003-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors GABRA3, GABBR1, GABRA2 DCTPP1 4649/4885HSD11B1 3021/4885GABRA1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.